Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837688 | PMC |
Publication Analysis
Top Keywords
Similar Publications
pH-mediated potentiation of gallium nitrate against .
Front Microbiol
September 2024
School of Public Health, Hebei Medical University, Shijiazhuang, China.
The emergence of multidrug-resistant isolates is a growing concern for public health, necessitating new therapeutic strategies. Gallium nitrate [Ga(NO)], a medication for cancer-related hypercalcemia, has attracted great attention due to its ability to inhibit growth and biofilm formation by disrupting iron metabolism. However, the antibacterial efficacy of Ga(NO) is not always satisfactory.
View Article and Find Full Text PDFMultiple Myeloma.
Home Healthc Now
May 2024
Mary C. Vrtis, PhD, MSN, RN, OCN, NEA-BC, FCN, is the Chief Executive Clinical Education, Nurses' Hands Across the Globe, Front Royal, Virginia.
Multiple myeloma (MM) is a cancer that arises from plasma cells in bone marrow. Approximately 35,730 Americans received a new diagnosis and MM will claim the lives of an estimated 12,590 people in 2023. Complications of the disease process include anemia, leukopenia, thrombocytopenia, renal failure, severe pain, bone loss, and hypercalcemia.
View Article and Find Full Text PDFEditorial: Cancer-related hypercalcemia and potential treatments.
Front Endocrinol (Lausanne)
October 2023
Clinic of Endocrinology and Diabetology, Lugano and Mendrisio Regional Hospital, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Synchronous Double Primary Cancer Complicated With Severe Hypercalcemia.
Cureus
August 2023
Internal Medicine, Hospital Distrital Santarém, Santarém, PRT.
Hypercalcemia of malignancy (HCM) is an important cancer-related medical emergency. It is a sign of advanced disease with a poor prognosis. We report a case of a 55-year-old man who presented with decreased sensorium, constipation for 4 days, dysphonia, and weight loss for the past three months.
View Article and Find Full Text PDFBone-modifying agents for non-small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review.
Semin Oncol
September 2023
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Electronic address:
During the course of lung cancer progression, bone metastases occur in about 40% of patients. Common complications associated with bone metastases in lung cancer patients include musculoskeletal pain, pathologic fractures, spinal cord compression, and hypercalcemia. We discuss the efficacy of bone-modifying agents (BMAs) in reducing skeletal-related events (SREs) and improving cancer-related outcomes, particularly in patients with stage IV non-small-cell lung cancer with bone metastases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!